Innovative therapeutics

Investors

NASDAQBMRN
FormDescriptionDateFormat
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Apr 25, 2017Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in HTML.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in DOC file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in PDF file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in XLS file.
DEFA14AAdditional proxy soliciting materials - definitiveApr 25, 2017Open Additional proxy soliciting materials - definitive in HTML.Open Additional proxy soliciting materials - definitive in DOC file.Open Additional proxy soliciting materials - definitive in PDF file.Open Additional proxy soliciting materials - definitive in XLS file.
PRE 14AA preliminary proxy statement providing notification matters to be brought to a voteApr 11, 2017Open A preliminary proxy statement providing notification matters to be brought to a vote in HTML.Open A preliminary proxy statement providing notification matters to be brought to a vote in DOC file.Open A preliminary proxy statement providing notification matters to be brought to a vote in PDF file.Open A preliminary proxy statement providing notification matters to be brought to a vote in XLS file.

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information